



COMPACT AUTOMATIC

CHEMILUMINESCENCE IMMUNOASSAY SYSTEM

Unstable Power? Reliable Operation with UPS.




MQ 60 smart



MQ 60 proB

MQ60 series mono-test automatic chemiluminescence immunoassay analyzers adopt chemiluminescence enzyme immunoassay technology with magnetic particle technology, through detecting the analyte substrate luminous intensity, to calculate the analyte concentration.



PRECISE

- ALP-AMPPD magnetic particle chemiluminescence
- Multiple quality controls available
- CV batch-to-batch $\leq 5\%$

FLEXIBLE

- Free parameters combination
- Standalone testing units

ECONOMY

- Single cartridge, no hidden cost
- No liquid circuit, limited maintenance

COMPACT

- Compact design suitable for small to large laboratories, clinical departments
- Diverse parameters covering cardiac diseases, tumor markers, fertility, thyroid, etc.

USER-FRIENDLY

- Large touch screen
- Fully automated, simple steps for operation

INTEGRATED UPS (OPTIONAL)

- Ensures uninterrupted operation during power outages.

Application



HOSPITAL LABORATORY



LABORATORY

Technical Specifications



MQ 60 smart

Analyzer Type	Fully automated Bench-top CLIA analyzer (MQ60 smart)
Sample type	Human serum, plasma, whole blood, urine
Host size	300mm x 565mm x 610mm (lengthxwidthxheight)
Host weight	36.0kg
Display	10.1 inch touch screen
Languages	English
Mode	Batch mode
Channel	6 channels
Throughput	24 tests/hour
Power supply	Voltage: AC 100-240V ~
Temperature control of incubation module	Temperature stability: 37°C ± 0.5°C Temperature fluctuation: not more than 0.5°C
PC	Integrated
Printer	Internal thermal printer
Storage	Result storage >1 million
Standby	24 hours operation standby
Data management	LIS/HIS connection

Analyzer Type	Fully automated Bench-top CLIA analyzer(MQ60 proB)
Sample type	Human serum, plasma, whole blood, urine
Host size	660mm x 750mm x 600mm (lengthxwidthxheight)
Host weight	80.0kg
Display	13.3 inch touch screen
Languages	English
Mode	Batch mode, STAT mode
Channel	2 modules, 12 channels
Throughput	48 tests/hour
Power supply	Voltage: AC 100-240V ~
Temperature control of incubation module	Temperature stability: 37°C ± 0.5°C Temperature fluctuation: not more than 0.5°C
PC	Integrated
Printer	Internal thermal printer
Storage	Result storage >10 million
Standby	24 hours operation standby
Data management	LIS/HIS connection



MQ 60 proB

Test Menu

Panel	Parameter	Qualification	Linear Range	Reference Values	Sample Type
Cardiac	hs-cTnT	CE IVDR	3-10000 pg/mL	<14 pg/mL	S/P/WB
	hs-cTnI	NMPA, CE IVDR	0.02-50 ng/mL	0.04 ng/mL	S/P/WB
	CK-MB	NMPA, CE IVDR	2-500 ng/mL	4.99 ng/mL	S/P/WB
	MYO	NMPA, CE IVDR	5-1000 ng/mL	48.8 ng/mL	S/P/WB
	H-FABP	NMPA, CE	0.2-300 ng/mL	10 ng/mL	S/P/WB
	Lp-PLA2	NMPA, CE	5-1000 ng/mL	200 ng/mL	S/P/WB
	NT-proBNP	NMPA, CE IVDR	50-30000 pg/mL	125 pg/mL	S/P/WB
	BNP	NMPA, CE IVDR	10-5000 pg/mL	105 pg/mL	S/P/WB
	ST2	NMPA	3-200 ng/mL	35 ng/mL	S/P/WB
	cTnI	NMPA	0.02-40 ng/mL	≤ 0.04 ng/mL	S/P/WB
Inflammation	D-Dimer	NMPA, CE IVDR	2.5-2500 ng/mL	350 ng/mL	P/WB
	PCT	NMPA, CE IVDR	0.02-100 ng/mL	0.05 ng/mL	S/P/WB
	PCTm	NMPA	0.15-100 ng/mL	0.5 ng/mL	WB
	CRP	NMPA, CE IVDR	0.5-150 mg/L	For evaluation of infection: Normal CRP < 8 mg/L. For risk stratification of cardiovascular disease: Low risk: 3.0 mg/L. Medium risk: 1.0-3.0 mg/L. High risk: >3.0 mg/L.	S/P/WB
	IL-6	NMPA, CE IVDR	1.5-5000 pg/mL	7 pg/mL	S/P/WB
Tumor	CEA	NMPA, CE IVDR	0.2-1000 ng/mL	5.2 ng/mL	S/P
	CA125	NMPA, CE IVDR	0.6-5000 U/mL	35 U/mL	S/P
	HE4	NMPA, CE IVDR	15-1500 pmol/L	105 pmol/L	S/P
	CYFRA21-1	NMPA, CE IVDR	0.1-500 ng/mL	3.3 ng/mL	S/P
	CA15-3	NMPA, CE IVDR	1-300 U/mL	26.4 U/mL	S/P
	CA242	NMPA	0.5-200 IU/mL	10 IU/mL	S
	CA19-9	NMPA, CE IVDR	0.6-1000 U/mL	27 U/mL	S/P
	CA72-4	NMPA	0.2-300 U/mL	6.9 U/mL	S/P
	CA50	NMPA	1-500 U/mL	25 U/mL	S/P
	NSE	NMPA	0.1-300 ng/mL	16.3 ng/mL	S
	proGRP	NMPA	3-2300 pg/mL	63 pg/mL	S/P
	SCCA	NMPA, CE IVDR	0.1-45 ng/mL	2.3 ng/mL	S/P
	tPSA	NMPA, CE IVDR	0.1-100 ng/mL	4 ng/mL	S/P
	VEGF	NMPA	50-3200 pg/mL	≤ 160 pg/mL	S
	fPSA	NMPA, CE	0.01-30 ng/mL	≤ 1.2 ng/mL	S
Liver Disease	TK1	NMPA	1.5-20 pM	≤ 2.02 pM	S/P
	AFP	NMPA, CE IVDR	0.6-1200 ng/mL	7 ng/mL	S/P
	AFP-L3%	NMPA, CE	5%-50%	<10%	S/P
	DCP	NMPA, CE	5-20000 ng/mL	40 ng/mL	S
	GP73	NMPA, CE	50-500 ng/mL	150 ng/mL	S/P
	CK18-M30	NMPA	Qualitative	200 U/L	S
Gastric Function	CK18-M65	NMPA	Qualitative	460 U/L	S
	G-17	NMPA	20-1000 pg/mL	<43.68 pg/mL	S/P
	PGI	NMPA	1-200 ng/mL	70 ng/mL. The reference value of PG I/PG II ratio in normal samples was above 3 when PG I and PG II combined detection was performed.	S/P
	PGII	NMPA	0.5-100 ng/mL	<23.85 ng/mL. The reference value of PG I/PG II ratio in normal samples was above 3 when PG I and PG II combined detection was performed.	S/P
	H. pylori Ab	NMPA	Qualitative	1.0 COI	S/P
Renal Function	H. pylori Urease Ab	/	Qualitative	1.0 COI	S/P
	NGAL	NMPA, CE	10-1000 ng/mL	145 ng/mL	S/Urine
	CysC	NMPA, CE	0.02-4 mg/L	1.2 mg/L	S/P/WB
Brain Injury	Anti-PLA2R IgG	NMPA	6-1500 RU/mL	<20.00 RU/mL	S/P
	S100	NMPA	0.02-30 ng/mL	0.105 ng/mL	S
Anemia	Ferr	NMPA, CE IVDR	0.5-2000 ng/mL	Male: 30-400 ng/mL; Female: 13-150 ng/mL.	S/P
	VB12	NMPA, CE IVDR	100-1800 pg/mL	190 pg/mL-910 pg/mL	S/P
	FA	NMPA, CE IVDR	1.0-24.0 ng/mL	3.5-20 ng/mL	S/P
Thyroid	TSH	NMPA, CE IVDR	0.1-100 mIU/L	0.27 mIU/L-4.2 mIU/L	S/P
	TT4	NMPA, CE IVDR	10-240 ng/mL	51-141 ng/mL	S/P
	TT3	NMPA, CE IVDR	0.25-6.0 ng/mL	0.8-2.0 ng/mL	S/P

Test Menu

Panel	Parameter	Qualification	Linear Range	Reference Values	Sample Type
Thyroid	FT4	NMPA, CE IVDR	1.0-76 pg/mL	9.3 pg/mL-17 pg/mL	S/P
	FT3	NMPA, CE IVDR	0.95-32 pg/mL	2.0 pg/mL-4.4 pg/mL	S/P
	Anti-TG	NMPA, CE IVDR	15-4000 IU/mL	115 IU/mL	S/P
	Anti-TPO	NMPA, CE IVDR	5.0-600 IU/mL	34 IU/mL	S/P
Immuog-lobulins	IgE	CE	0.5-1500 IU/mL	Age group: New born: <1.5 IU/mL; 1-12 months: <15 IU/mL; 1-5 years old: <60 IU/mL; 6-9 years old: <90 IU/mL; 10-15 years old: <200 IU/mL; Adult: <100 IU/mL.	S/P
Sex hormone	FSH	NMPA, CE IVDR	0.5-200 IU/L	Male: 1.5-12.3 IU/L; Female: Follicular phase: 3.5-12.5 IU/L; Ovulation phase: 4.7-21.5 IU/L; Luteal phase: 1.7-7.7 IU/L; After menopause: 25.8-134.5 IU/L;	S/P
	E2	NMPA, CE IVDR	10-3000 pg/mL	Male: 25.1-60.5 pg/mL; Female: Follicular phase: 12.3-233 pg/mL; Ovulation phase: 41-398 pg/mL; Luteal phase: 22.5-341 pg/mL; After menopause: <10-138 pg/mL; Pregnancy early phase: 155->3000 pg/mL.	S/P
	T	NMPA, CE IVDR	0.10-15 ng/mL	Male: 1.93-8.36 ng/mL; Female: 0.10-0.48 ng/mL.	S/P
	P	NMPA, CE IVDR	0.10-50 ng/mL	Male: 0.2-1.4 ng/mL; Female: Follicular phase: 0.2-1.5 ng/mL; Ovulation phase: 0.8-3.0 ng/mL; Luteal phase: 1.7-27 ng/mL; After menopause: 0.1-0.8 mL.	S/P
	LH	NMPA, CE IVDR	1.0-200 IU/L	Male: 1.7-8.6 IU/L; Female: Follicular phase: 2.3-12.5 IU/L; Ovulation phase: 14.0-95.0 IU/L; Luteal phase: 1.1-11.4 IU/L; After menopause: 7.7-58.5 IU/L.	S/P
	PRL	NMPA, CE IVDR	5.0-5000 mIU/L	Male: 55-325 mIU/L; Female (Non-pregnant): 101-495 mIU/L.	S/P
	AMH	NMPA, CE IVDR	0.05-23 ng/mL	Female: Age group: 20-39: 0.5-9.95 ng/mL; 40-50: 0.05-4.44 ng/mL.	S/P
	β-HCG	NMPA, CE IVDR	2-15000 mIU/mL	Non-pregnant women: 5.2 mIU/mL; Pregnant women: 1-10 weeks: 200-230080 mIU/mL; 11-15 weeks: 22540-234900 mIU/mL; 16-22 weeks: 8050-50100 mIU/mL; 23-40 weeks: 1620-49445 mIU/mL.	S/P
	Inhibin B	CE	10-1300 pg/mL	Male: 18.42-270.30 pg/mL; Female: Age group: 20-50: 14.25-97.53 pg/mL; >50: <10-13.27 pg/mL.	/
Growth Hormone	GH	NMPA	0.06-40 ng/mL	Male: Age group: 1-10: 0.097-6.27 ng/mL; 11-18: 0.081-10.76 ng/mL; 19-79: 0.041-2.41 ng/mL; Female: Age group: 1-10: 0.118-7.78 ng/mL; 11-18: 0.128-8.00 ng/mL; 19-77: 0.128-9.85 ng/mL.	S/P
	IGFBP-3	NMPA	0.1-16 µg/mL	Age group: 1-6: 0.726-5.17 µg/mL; 7-10: 1.47-7.22 µg/mL; 11-18: 2.9-8.99 µg/mL; 19-64: 3.09-7.56 µg/mL; 65-80: 2.89-5.62 µg/mL.	S/P
	IGF-1	/	/	/	/
Diabetes	HbA1c	NMPA, CE IVDR	4%-16%	4.0%-6.0%	WB
	C-P	NMPA, CE	0.01-40 ng/mL	1.02-4.31 ng/mL	S/P
	INS	NMPA, CE	0.2-1000 µIU/mL	2.16-25.1 µIU/mL	S/P
	ADP	NMPA	0.1-60 µg/mL	0.92 µg/mL-13.51 µg/mL	S/P
	GADA	NMPA	5-250 IU/mL	10 IU/mL	S/P
	IA-2A	NMPA	5-250 IU/mL	10 IU/mL	S/P
	IAA	NMPA	Qualitative	1.0 COI	S/P
	ICA	NMPA	Qualitative	1.0 COI	S/P
Hypertension	Cortisol	NMPA, CE	0.4-60 µg/dL	Morning: 6.6-23.1 µg/dL; Afternoon: 10.3 µg/dL	S/P/Urine
	ALD	NMPA, CE	20-1000 pg/mL	Standing position: 70-300 pg/mL; Lying down position: 30-160 pg/mL.	S/P
	Renin	NMPA, CE	0.5-500 pg/mL	Standing position: 2.8-28.4 pg/mL; Lying down position: 1.9-24.5 pg/mL.	P
	ACTH	NMPA	1-2000 pg/mL	7.20-63.5 pg/mL	P
Bone Metabolism	25-OH-VD	NMPA, CE IVDR	3-120 ng/mL	30-150 ng/mL	S/P
	PTH	NMPA, CE	5.5-2300 pg/mL	14.28-56.15 pg/mL	S/P
	BGP	NMPA, CE	0.5-300 ng/mL	Healthy male: Age group: 18-<30: 24.05-70.21 ng/mL; 30-50: 14.22-42.05 ng/mL; >50-70: 14.30-46.03 ng/mL; Female: Healthy female: Premenopausal: 11.17-43.12 ng/mL; Postmenopausal: 15.09-46.23 ng/mL; Patients with osteoporosis: 13.21-48.02 ng/mL.	S/P
	Total P1NP	NMPA	5-1200 ng/mL	Premenopausal women: 15.25-58.83 ng/mL; Postmenopausal women: 16.12-73.17 ng/mL.	S/P
	β-CTx	NMPA	0.01-6 ng/mL	Male: Age group: 30-50: 0.585 ng/mL; >50-70: 0.711 ng/mL; >70: 0.859 ng/mL; Female: Premenopausal: 0.576 ng/mL; Postmenopausal: 1.042 ng/mL.	S/P
	Anti-CCP	NMPA, CE IVDR	10-500 U/mL	≤ 17.30 U/mL	S/P
Rheumatoid Arthritis	RF-IgA	NMPA	2-200 RU/mL	<20 RU/mL	S/P
	RF-IgM	NMPA	2-200 RU/mL	<20 RU/mL	S/P
	RF-IgG	NMPA	2-200 RU/mL	<20 RU/mL	S/P
	IL-2	NMPA, CE	2.5-1000 pg/mL	12 pg/mL	S
Cytokine	IL-4	NMPA	2.5-2500 pg/mL	12.8 pg/mL	S/P
	IL-5	NMPA	2.5-2500 pg/mL	5.9 pg/mL	S
	IL-8	NMPA, CE	5-7500 pg/mL	63 pg/mL	S
	IL-10	NMPA, CE	3-1000 pg/mL	9.5 pg/mL	S

Panel	Parameter	Qualification	Linear Range	Reference Values	Sample Type
Cytokine	IL-1β	NMPA, CE	3-1000 pg/mL	4.9 pg/mL	S
	TNFα	NMPA, CE	3-1000 pg/mL	8.5 pg/mL	S
	IL-2R	NMPA,CE IVDR	5-7500 U/mL	228-724 U/mL	S/P
	IL-17A	NMPA	2.5-2500 pg/mL	5.6 pg/mL	S/P
	IFN-γ	NMPA, CE	2-1000 IU/mL	4 IU/mL	S/P
	IL-12p70	NMPA	2.5-1000 pg/mL	10.5 pg/mL	S
	IL-22	NMPA	1-1000 pg/mL	3.71 pg/mL	S
TORCH	Toxo-IgG	/	Qualitative	1.0 COI	S/P
	Toxo-IgM	/	Qualitative	1.0 COI	S/P
	RUB-IgG	/	Qualitative	1.0 COI	S/P
	RUB-IgM	/	Qualitative	1.0 COI	S/P
	CMV-IgG	/	Qualitative	1.0 COI	S/P
	CMV-IgM	/	Qualitative	1.0 COI	S/P
	HSV-1/2 IgG	/	Qualitative	1.0 COI	S/P
	HSV-1/2 IgM	/	Qualitative	1.0 COI	S/P
	HSV-1 IgG	/	Qualitative	1.0 COI	S/P
	HSV-1 IgM	/	Qualitative	1.0 COI	S/P
	HSV-2 IgG	/	Qualitative	1.0 COI	S/P
	HSV-2 IgM	/	Qualitative	1.0 COI	S/P
STAT	PCT STAT	NMPA	0.02-100 ng/mL	≤ 0.05 ng/mL	S/P/WB
	H-FABP STAT	NMPA	0.2-120 ng/mL	≤ 8.3 ng/mL	S/P/WB
	NGAL STAT	NMPA	10-1000 ng/mL	≤ 145 ng/mL	S
	MYO STAT	NMPA	5-1000 ng/mL	≤ 48.8 ng/mL	S/P/WB
	BNP STAT	NMPA	10-5000 pg/mL	≤ 105 pg/mL	P/WB
	IL-6 STAT	NMPA	1.5-5000 pg/mL	≤ 7 pg/mL	S/P/WB
	D-Dimer STAT	NMPA	50-10000 ng/mL	≤ 500 ng/mL	P/WB
	NT-proBNP STAT	NMPA	30-30000 pg/mL	Age group: 1-18: 263.8 pg/mL; 19-49: 125.0 pg/mL; 50-75: 275.8 pg/mL; >75: 582.9 pg/mL	S/P/WB
	hs-cTnI STAT	NMPA	0.02-40 ng/mL	≤ 0.04 ng/mL	S/P/WB
	CK-MB STAT	NMPA	2-400 ng/mL	≤ 4.99 ng/mL	S/P/WB
Infectious Disease	HBsAg	/	0.05-150 IU/mL	0.1 IU/mL	S/P
	HCV-Ab	/	Qualitative	1.0 COI	S/P
	HIV-Ab/Ag	/	Qualitative	1.0 COI	S/P
	TP-Ab	/	Qualitative	1.0 COI	S/P
Tuberculosis (TB-IGRA)	Protein extraction reagent	NMPA, CE IVDR	/	/	WB
	IFN-γ	NMPA, CE	2-1000 IU/mL	4 IU/mL	S/P

• Available • Coming soon